Clary Estes

5 days ago | bio.news | Clary Estes

Over 7 million Americans live with Alzheimer’s disease, according to the Alzheimer’s Association. For June’s Alzheimer’s Awareness Month, Bio.News sat down with the Alzheimer’s Association to talk about the top four things to know about the disease. Many wonder what the difference is between Alzheimer’s and dementia. As the Alzheimer’s Association explains, dementia is an umbrella term for a particular group of symptoms, one cause of which is Alzheimer’s disease.

1 week ago | bio.news | Clary Estes

Established in 2012, the Pediatric Priority Review (PPRV) program offers a powerful incentive for companies to develop treatments for rare conditions affecting children. Even though the program was incredibly successful in helping spur drug development for some of the most challenging rare diseases, the program’s authorization expired in 2024. As such, patient advocates and drug developers who are working in the rare disease space have been calling for its reauthorization.

1 week ago | bio.news | Clary Estes

The 2025 Biotechnology Innovation Organization (BIO) International Convention highlighted why we – the biotech industry – do what we do. In one word: patients. On Day 3, a panel, “Recognizing the Why Behind Our Medicines: Patient Connection as a Motivator for Impact,” featured patient advocates and biotech leaders examining the importance of putting patients front of mind in everything that they do.

1 week ago | bio.news | Clary Estes

The rare disease patient community is the beating heart of the Biotechnology Innovation Organization’s (BIO) mission. Whether it is driving policy that supports innovation, improving coordination with regulatory bodies, or facilitating partnerships, BIO is committed to helping rare disease patients live longer, healthier lives. Rare disease has been a major theme at the 2025 BIO International Convention. As many of the discussions from the week have shown, rare disease patients can’t wait.

1 week ago | bio.news | Clary Estes

Food and Drug Administration (FDA) Commissioner Martin A. Makary, M.D., M.P.H., sat down with the Biotechnology Innovation Organization (BIO) President and CEO John F. Crowley to discuss his vision for the FDA. “It’s been exhilarating to meet so many of you,” said Dr. Makary, who assumed his role in March 2025. “And also hear what your ideas are for the FDA.”He discussed topics including communication with sponsors, structural and staffing changes at FDA, and why he’s excited about AI.